ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

2-(1-メチル-1H-イミダゾール-4-イル)酢酸

1-Methylimidazoleacetic acid

HCID 75810
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
2625-49-2
標準SMILES
Cn1cnc(CC(=O)O)c1
InChIKey
ZHCKPJGJQOPTLB-UHFFFAOYSA-N
分子式
C6H8N2O2
平均分子量
140.14 g/mol
単同位体質量
140.0585775

概要

1-methyl-4-imidazoleacetic acid is a monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by a 1-methyl-1H-imidazol-4-yl group. It has a role as a metabolite and a GABA agonist. It is a member of imidazoles and a monocarboxylic acid. It is functionally related to an acetic acid. It is a conjugate acid of a 1-methyl-4-imidazoleacetate.

名称と識別子

優先名称
1-Methylimidazoleacetic acid
IUPAC
2-(1-methylimidazol-4-yl)acetic acid
現地名
2-(1-メチル-1H-イミダゾール-4-イル)酢酸
英語名
(1-Methyl-1H-imidazol-4-yl)-acetic acid
分子式
C6H8N2O2
分子量
140.14

名称と別名

2625-49-2Methylimidazoleacetic acid1H-Imidazole-4-acetic acid, 1-methyl-1-METHYLIMIDAZOLEACETIC ACIDEKP351892FDTXSID30180884RefChem:818627DTXCID701033752-(1-methyl-1H-imidazol-4-yl)acetic acid2-(1-methylimidazol-4-yl)acetic acid1-Methyl-4-imidazoleacetic acid(1-METHYL-1H-IMIDAZOL-4-YL)-ACETIC ACID
名称をさらに表示
2-(1-メチル-1H-イミダゾール-4-イル)酢酸2-(1-Methyl-4-Imidazolyl)Acetic Acid
Tele-methylimidazoleacetic acidMethylimidazoleacetateMFCD086682901,4-methyl-imidazoleacetic acid1-Methylimidazole-4-acetate(1-methyl-1H-imidazol-4-yl)acetic acidn-methylimidazoleacetic acid1-methylimidazole-4-acetic acid

データベース識別子

CAS
2625-49-2
PubChem CID
75810
DTXSID
DTXSID30180884
ChEBI
CHEBI:1606
UNII
EKP351892F

物性

構造計算による物性補完中

XLogP
-0.5
極性表面積
55.1 Ų
水素結合供与体数
1
水素結合受容体数
3
回転可能結合数
2
重原子数
10
形式電荷
0
複雑度
138

実験および物理化学的性質

Color/FormCrystalline solid
SolubilitySolubility: Approx 10 mg/L in PBS /phosphate-buffered saline/ (pH 7.2); appeoxmately 10 mg/mL in DMSO; Approximately 2 mg/mL in ethanol, DMF /Methylimidazoleacetic acid, monohydrochloride/
Physical DescriptionSolid
Other Experimental Properties · 2 件

Crystalline solid. MW 176.6. /Methylimidazoleacetic acid, monohydrochloride/

lambda max: 214 nm /Methylimidazole acetic acid, monohydrochloride/

物理化学的性質

融点
187 · 187-189 °C
沸点
384.4 · 384.4±17.0 °C(Predicted)
比重(密度)
1.27 · 1.27±0.1 g/cm3(Predicted)
貯蔵温度
2 · 2-8°C
外見
Solid
酸解離定数(Pka)
3.44 · 3.44±0.10(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesSkin Irrit. 2 (100%)

安全と保護具

Disposal Methods · 1 件

SRP: Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in air, soil or water; effects on animal, aquatic and plant life; and conformance with environmental and public health regulations. If it is possible or reasonable use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination.

毒性情報

Toxicity SummaryIDENTIFICATION AND USE: Methylimidazoleacetic acid is a urinary metabolite of histamine and end-product of histamine metabolism. HUMAN STUDIES: There are no data available. ANIMAL STUDIES: There are no data available.
Natural Pollution SourcesMethyimidazoleacetate is a urinary metabolite of histamine and end-product of histamine metabolism.
Artificial Pollution SourcesMethylimidazoleacetic acid's production and use as a research chemical(1) may result in its release to the environment through various waste streams(SRC).

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

In mammalian brain, histamine is known to be metabolized solely by histamine methyltransferase (HMT), forming tele-methylhistamine (t-MH), then tele-methylimidazoleacetic acid (t-MIAA). We previously showed that imidazoleacetic acid (IAA), a GABA agonist, and histamine's metabolite in the periphery, is present in brain where its concentration increased after inhibition of HMT. Also, when [3H]histamine was given intracerebro-ventricularly to rats, a portion was converted to IAA, a process increased by inhibition of HMT. These results indicated that brain has the capacity to oxidize histamine but did not show whether this pathway is operative under physiological conditions. To address this question, rats were infused for > 4 weeks with alpha-fluoromethylhistidine (alpha-FMHis), an irreversible inhibitor of histamine's synthetic enzyme, L-histidine decarboxylase. Compared with controls (untreated and saline-treated rats), brain levels of histamine, t-MH, and t-MIAA in all regions were markedly reduced in treated rats. As a percentage of controls, depletion of t-MIAA > t-MH > histamine in all regions, and regional depletions of histamine co-responded to its turnover rates in regions of rat brain. In contrast, levels of IAA were unchanged as were levels of pros-methylimidazoleacetic acid, an isomer of t-MIAA unrelated to histamine metabolism. Results suggest that in brains of rats, unlike in the periphery, most IAA may not normally derive from histamine. Because histamine in brain can be converted to IAA under certain conditions, direct oxidation of histamine may be a conditional phenomenon. Our results also support the existence of a very slow turnover pool of brain histamine and use of chronic alpha-FMHis infusion as a model to probe the histaminergic system in brain.

Absorption, Distribution and Excretion · 3 件

AIM: To study histidine decarboxylase (HDC) expression in normal and neoplastic gastric neuroendocrine cells in relationship to the main histamine metabolite. METHODS: Control tissues from fundus (n = 3) and corpus (n = 3) mucosa of six patients undergoing operations for gastric adenocarcinoma, biopsy and/or gastric surgical specimens from 64 patients with primary gastric neuroendocrine tumours (GNETs), as well as metastases from 22 of these patients, were investigated using conventional immunohistochemistry and double immunofluorescence with commercial antibodies vs vesicular monoamine transporter 2 (VMAT-2), HDC and ghrelin. The urinary excretion of the main histamine metabolite methylimidazoleacetic acid (U-MeImAA) was determined using high-performance liquid chromatography in 27 of the 64 patients. RESULTS: In the gastric mucosa of the control tissues, co-localization studies identified neuroendocrine cells that showed immunoreactivity only to VMAT-2 and others with reactivity only to HDC. A third cell population co-expressed both antigens. There was no co-expression of HDC and ghrelin. Similar results were obtained in the foci of neuroendocrine cell hyperplasia associated with chronic atrophic gastritis type A and also in the tumors. The relative incidence of the three aforementioned markers varied in the tumors that were examined using conventional immunohistochemistry. All of these GNETs revealed both VMAT-2 and HDC immunoreactivity, and their metastases showed an immunohistochemical pattern and frequency similar to that of their primary tumors. In four patients, increased U-MeImAA excretion was detected, but only two of the patients exhibited related endocrine symptoms. CONCLUSION: Human enterochromaffin-like cells appear to partially co-express VMAT-2 and HDC. Co-expression of VMAT-2 and HDC might be required for increased histamine production in patients with GNETs.

関連反応

18 件
反応記録を作成
HRID 139657 の反応式
HRID 139657反応物として
HRID 325230 の反応式
HRID 325230反応物として
HRID 383101 の反応式
HRID 383101反応物として
HRID 1043296 の反応式
HRID 1043296反応物として
HRID 1043297 の反応式
HRID 1043297反応物として
HRID 1423189 の反応式
HRID 1423189反応物として
HRID 1428021 の反応式
HRID 1428021反応物として
HRID 1428022 の反応式
HRID 1428022反応物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
EC Number
112-449-0
Nikkaji
J257.475F
Antidote and Emergency Treatment · 3 件

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) or lorazepam (Ativan) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

安全データ

有毒物質データの
2625-49-2(Hazardous Substances Data)

Similar to metabolites of other aminergic transmitters, histamine metabolites of brain, tele-methylhistamine (t-MH) and tele-methylimidazoleacetic acid (t-MIAA), could have a concentration gradient between rostral and caudal sites of CSF. To test this hypothesis, cisternal and lumbar CSF samples were collected in pairs from eight monkeys (Macaca mulatta), and levels of t-MH and t-MIAA were measured by gas chromatography-mass spectrometry. pros-Methylimidazoleacetic acid (p-MIAA), an endogenous isomer of t-MIAA that is not a histamine metabolite, was also measured. Cisternal levels (in picomoles per milliliter, mean +/- SEM) of t-MH (9.9 +/- 1.4) and t-MIAA (40.8 +/- 7.6), but not of p-MIAA (9.7 +/- 1.2), exceeded those in lumbar CSF (t-MH, 1.8 +/- 0.3; t-MIAA, 6.8 +/- 0.9; p-MIAA, 8.6 +/- 0.6) in every monkey. The magnitudes of the mean cisternal-lumbar concentration gradients for t-MH (6.6 +/- 1.1) and t-MIAA (6.5 +/- 1.3) were indistinguishable. These gradients exceed those of metabolites of most other transmitters. There was no gradient for the levels of p-MIAA. The cisternal, but not lumbar, levels of t-MH and t-MIAA were correlated. There was no significant difference between the means of the metabolite concentration ratios (t-MIAA/t-MH) in cisternal (4.0 +/- 0.4) and lumbar (4.4 +/- 0.9) CSF. The steepness of these gradients suggests that levels of t-MH and t-MIAA in lumbar CSF might be useful probes of histaminergic metabolism in brain.

tele-Methylimidazoleacetic acid (t-MIAA), a major brain histamine metabolite, was measured in nine rat brain regions by a gas chromatography-mass spectrometric method that also measures the precursor amine, tele-methylhistamine (t-MH). The t-MIAA concentration of cerebellum, medulla-pons, midbrain, caudate nucleus, hypothalamus, frontal cortex, hippocampus, and thalamus varied 15-fold, hypothalamus showing the highest level (2.21 nmol/g) and cerebellum the lowest (0.15 nmol/g). The concentrations of t-MIAA and t-MH were significantly correlated in all regions except midbrain, which had relatively more t-MIAA. Probenecid did not alter whole-brain t-MIAA levels. Treatment with pargyline, an inhibitor of monoamine oxidase, lowered the t-MIAA levels in all regions.

Tissue LocationsBrain
Cellular LocationsExtracellular
Metabolite PathwaysHistidine metabolism

補足説明

定義ChEBI: An imidazolyl carboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1-methyl-1H-imidazol-4-yl group.